Hematopoietic stem cell transplantation for CD40 ligand deficiency: Results from an EBMT/ESID-IEWP-SCETIDE-PIDTC study


Creative Commons License

Ferrua F., Galimberti S., Courteille V., Slatter M. A., Booth C., Moshous D., ...Daha Fazla

JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY, cilt.143, sa.6, ss.2238-2253, 2019 (SCI-Expanded, Scopus) identifier identifier identifier

  • Yayın Türü: Makale / Tam Makale
  • Cilt numarası: 143 Sayı: 6
  • Basım Tarihi: 2019
  • Doi Numarası: 10.1016/j.jaci.2018.12.1010
  • Dergi Adı: JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY
  • Derginin Tarandığı İndeksler: Science Citation Index Expanded (SCI-EXPANDED), Scopus
  • Sayfa Sayıları: ss.2238-2253
  • Anahtar Kelimeler: CD40 ligand, hematopoietic stem cell transplantation, X-linked hyper-IgM syndrome, primary immunodeficiency, BONE-MARROW-TRANSPLANTATION, HYPER-IGM SYNDROME, X-LINKED IMMUNODEFICIENCY, IMMUNOGLOBULIN-M SYNDROME, DEFECTIVE EXPRESSION, CLINICAL-FEATURES, T-CELLS, CHILDREN, EXPERIENCE, MUTATIONS
  • Açık Arşiv Koleksiyonu: AVESİS Açık Erişim Koleksiyonu
  • Ankara Üniversitesi Adresli: Evet

Özet

Background: CD40 ligand (CD40L) deficiency, an X-linked primary immunodeficiency, causes recurrent sinopulmonary, Pneumocystis and Cryptosporidium species infections. Long-term survival with supportive therapy is poor. Currently, the only curative treatment is hematopoietic stem cell transplantation (HSCT).